Compare CTKB & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | BBNX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 493.1M |
| IPO Year | 2021 | 2025 |
| Metric | CTKB | BBNX |
|---|---|---|
| Price | $4.89 | $20.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.63 | ★ $23.80 |
| AVG Volume (30 Days) | 764.1K | ★ 977.3K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,015,000.00 | $100,251,000.00 |
| Revenue This Year | $5.42 | $34.90 |
| Revenue Next Year | $7.03 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.67 | ★ 53.94 |
| 52 Week Low | $3.28 | $8.80 |
| 52 Week High | $6.18 | $32.71 |
| Indicator | CTKB | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.91 | 56.57 |
| Support Level | $4.17 | $9.34 |
| Resistance Level | $5.24 | $20.48 |
| Average True Range (ATR) | 0.20 | 1.25 |
| MACD | 0.01 | -0.31 |
| Stochastic Oscillator | 75.93 | 78.81 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.